Skip to content. | Skip to navigation

Personal tools
Log in


You are here: Home / Faculty / Dr. Aly Karsan, MD / Publications-Complete / Publications - Aly Karsan

Publications - Aly Karsan

Updated June 2018
  1. Blais J, Giroux S, Caron A, Clément V, Dionne-Laporte A, Jouan L, Gauthier J, MacLeod T, Moore R, Parker J, Swanson L, Zhao Y, Rouleau G, Karsan A, Langlois S, Rousseau F. Non-invasive prenatal aneuploidy testing: Critical diagnostic performance parameters predict sample z-score values. Clin Biochem. 2018 Jun 26. pii: S0009-9120(18)30491-0. doi: 10.1016/j.clinbiochem.2018.06.015. [Epub ahead of print]. PMID: 29958880

  2. Lam J, Van Den Bosch M, Wegrzyn-Woltosz J, Parker J, Ibrahim R, Slowski K, Chang L,Martinez-Hoyer S, Umlandt P, Fuller M, Karsan A. Loss of miR-143 and miR-145 inhibithematopoietic stem cell activity but enhance progenitor activity through activation of TGFβ signaling. Nature Communications volume 9, Article number: 2418 (2018).

  3. Wegrzyn-Woltosz J, Parker J, Ibrahim R, Fuller M, Deng D, Kim A, Umlandt P, Imren S, Humphries R, Karsan A. Activation of IGF-1R signaling secondary to haploinsufficiency of miR-143 and miR-145 reveals a targetable dependency of del(5q) MDS. Submitted.

  4. Paliouras GN, Coulombe P, Clayton A, Hussainkhel A, Fuller M, Dauphinee S, Umlandt P, Kyle AH, Minchinton AI, Parker JDK, Wright JL, Karsan A. Endothelial Sash1 is required for alveolar surfactant production through nitric oxide signaling. Dev Cell. In Revision 

  5. Bidshahri R, Fakhfakh K, McNeil K, Karsan A, Won JR, Wolber R, Hughesman C, Haynes C. Quantitative analysis of KRAS G12/G13 status in colorectal cancer using a novel wild-type negative assay that unequivocally differentiates missense and synonymous alleles. J Mol Diagn. Submitted

  6. Hui T, O'Neil K, Wegrzyn-Woltosz J, Laks E, Mingay M, Moksa M, Aparicio S, Karsan A, Hirst M. Single-cell epigenetic heterogeneity within the hematopoietic stem cell compartment. Nature Methods. Submitted

  7. Agrahari R, Foroushani A, Docking TR, Chang L, Duns G, Hudoba M, Karsan A*, Zare H*. Applications of Bayesian network models in predicting types of hematological malignancies. *co-senior authors Scientific Reports. Sci Rep. 2018 May 3;8(1):6951. doi: 10.1038/s41598-018-24758-5. PMID: 29725024

  8. Stockley T,  Souza C, Cheema P, Melosky B,  Kamel-Reid S, Tsao M,  Spatz A, Karsan A. Evidence-Based Best Practices for EGFR-T790M Testing in Lung Cancer in Canada. Curr Oncol. 2018 Apr; 25(2): 163–169. Published online 2018 Apr 30. doi:  10.3747/co.25.4044 PMID: 29719432

  9. Cremin C, Howard S, Le L, Karsan A, Schaeffer DF, Renouf D, Schrader KA. CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome. Hered Cancer Clin Pract. 2018 Mar 7;16:7. doi: 10.1186/s13053-018-0088-y. eCollection 2018. PMID:29541281

  10. Liu K, Lu XJ, Cheng Y, Klieb H, Ng S, McNeil K, Karsan A, Poh C. An actionable test using loss of heterozygosity in identifying high-risk oral premalignant lesions. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Dec 18. pii: S2212-4403(17)31208-7. doi: 10.1016/j.oooo.2017.10.019. PMID: 29428696

  11. Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM. Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941. PMID 29246904

  12. Enfield K,  Marshall E,  Ng K, Anderson C,  Rahmati S,  Lam S,  Macaulay C,  Lockwood W,  Karsan A,  Jurisica I,  Lam W. Inhibition of the Novel Oncogene ELF3 Abolishes Lung Adenocarcinoma Growth. Journal of Thoracic Oncology. November 2017 Volume 12, Issue 11, Supplement 2, Page S1763 DOI:

  13. Tsao M, Zhang T, Cheema P, Laskin J, Karsan A, Barnes T, Liu G, Owen S, Rothenstein J, Burkes R,  Iqbal M, Spatz A, Izevbaye I, Kempen L, Kamel-Reid S, Leighl N. Canadian Multicenter Validation Study of Plasma Circulating Tumor DNA for Epidermal Growth Factor (EGFR) T790M Testing Journal of Thoracic Oncology, November 2017, Volume 12, Issue 11, Supplement 2, Page S2207 DOI:

  14. Grewal JK, Eirew P, Jones M, Chiu K, Tessier-Cloutier B, Karnezis AN, Karsan A, Mungall A, Zhou C, Yip S, Tinker AV, Laskin J, Marra M, Jones SJM. Detection and Genomic Characterization of a mammary-like adenocarcinoma. Cold Spring Harb Mol Case Stud. 2017 Nov 21;3(6). pii: a002170. doi: 10.1101/mcs.a002170. PMID: 28877932

  15. Lai CK, Norddahl GL, Maetzig T, Rosten P, Lohr T, Sanchez Milde L, von Krosigk N, Docking TR, Heuser M, Karsan A, Humphries RK. Meis2 as a critical player in MN1-induced leukemia. Blood Cancer J. 2017 Sep 29;7(9):e613. doi: 10.1038/bcj.2017.86. PMID: 28960191

  16. Yi Y, Tsai SH, Cheng JC, Wang EY, Anglesio MS, Cochrane DR, Fuller M, Gibb EA, Wei W, Huntsman DG, Karsan A, Hoodless PA. APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. Gynecol Oncol. 2017 Dec;147(3):663-671. doi: 10.1016/j.ygyno.2017.10.016. December 2017. PMID: 29079036

  17. Wong HL, Yang KC, Shen Y, Zhao EY, Loree JM, Kennecke HF, Kalloger SE, Karasinska JM, Lim HJ, Mungall AJ, Feng X, Davies JM, Schrader K, Zhou C, Karsan A, Jones SJ, Laskin J, Marra MA, Schaeffer DF, Gorski SM, Renouf DJ. Molecular characterisation of metastatic pancreatic neuroendocrine tumours (PNETs) using whole genome and transcriptome sequencing. Cold Spring Harb Mol Case Stud. 2017 Nov 1. pii: mcs.a002329. doi: 10.1101/mcs.a002329. PMID:29092957

  18. Chang KTE, Goytain A, Tucker T, Karsan A, Lee CH, Nielsen TO, Ng TL. Development and Evaluation of a Pan-Sarcoma Fusion Gene Detection Assay Using the NanoString nCounter Platform. J Mol Diagn. 2017 Nov 17. pii: S1525-1578(17)30314-8. doi:10.1016/j.jmoldx.2017.09.007. PMID: 29104083

  19. Hout DR, Schweitzer BL, Lawrence K, Morris SW, Tucker T, Mazzola R, Skelton R, McMahon F, Handshoe J, Lesperance M, Karsan A, Saltman DL. Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer. Cancers (Basel). 2017 Aug 1;9(8). pii: E99. doi: 10.3390/cancers9080099 PMID: 28763012 

  20. Lebo MS, Zakoor KR, Chun K, Speevak MD, Waye JS, McCready E, Parboosingh JS, Lamont  RE, Feilotter H, Bosdet I, Tucker T, Young S, Karsan A, Charames GS, Agatep R, Spriggs EL, Chisholm C, Vasli N, Daoud H, Jarinova O, Tomaszewski R, Hume S, Taylor S, Akbari MR, Lerner-Ellis J; Canadian Open Genetics Repository Working Group. Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR).Genet Med. 2017 Jul 20. doi: 10.1038/gim.2017.80. PMID:28726806

  21. Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D,    Juergens RA, Butts C, and Tsao MS. Management of EGFR Mutated NSCLC: Practical Implications from   a Clinical and Pathology Perspective. Curr Oncol. 2017 Apr;24(2):111-119. doi: 10.3747/co.24.3524.  PMID: 28490925

  22. Weymann D, Laskin J, Roscoe R, Schrader I, Chia S, Yip S, Cheung W, Gelmon K, Karsan A, Renouf   D, Marra M, Regier D. The cost and cost-trajectory of whole-genome analysis guiding treatment of  patients with advanced cancers. Clin Genet. 2017 Mar 12;5(3):251-260. doi: 10.1002/mgg3.281. PMID: 28546995

  23. Thibodeau ML, Reisle C, Zhao E, Martin LA, Alwelaie Y, Mungall KL, Ch'ng C, Thomas R, Ng T, Yip S, J Lim H, Sun S, Young SS, Karsan A, Zhao Y, Mungall AJ, Moore RA, J Renouf D, Gelmon K, Ma YP, Hayes M, Laskin J, Marra MA, Schrader KA, Jones SJM. Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma. Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5). pii: a001628. doi: 10.1101/mcs.a001628. Print 2017 Sep. PMID: 28514723

  24. Goy J, Gillan T, Huang S, Karsan A, Ramadan K, Bruyere H, Toze C, Gerrie A, Hrynchak M and Connors J. Chronic lymphocytic leukemia patients with deletion 11q have a short time to requirement of  first-line therapy, but long overall survival: results of a population-based cohort in British Columbia, Canada. Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):382-389. pii: S2152-2650(17)30205-7. doi: 10.1016/j.clml.2017.04.001. PMID: 28559149

  25. O'Neill K, Hills M, Gottlieb M, Karsan A and Lansdorp P. Assembling Draft Genomes using contiBAIT. Bioinformatics. 2017 Sep 1;33(17):2737-2739. doi: 10.1093/bioinformatics/btx281. PMID: 28475666
  26. Foroushani A, Agrahari R, Docking R, Chang L, Duns G, Hudoba M, Karsan A*, Zare H* (co-senior authors). Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications. BMC Med Genomics. 2017 Mar 16;10(1):16. PMID: 28298217
  27. Huang SJ, Lee LJ, Gerrie AS, Gillan TL, Bruyere H, Hrynchak M, Smith AC, Karsan A, Ramadan KM, Jayasundara KS, and Toze CL. Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada. Leuk Res. 2017 Jan 15;55:79-90. PMID: 28157628
  28. Huang S, Gerrie A, Bergin K, Gillan T, Bruyere H, Smoth A, Ramadan K, Karsan A, Dalal C, Toze C, Azue K. Clonal evolution as detected by interphase fluorescence in situ hybridization is associated with worse overall survival in a population-based analysis of patients with chronic lymphocytic leukemia in British Columbia, Canada. Cancer Genet. 2017 Jan: 210:1-8. 
  29. Stunnenberg HG; International Human Epigenome Consortium, Hirst M. The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. Cell. 2016 Nov 17;167(5):1145-1149. PMID: 27863232
  30. Busque L, Porwit A, Day R, Olney H, Leber B, Ethier V, Sirhan S, Foltz L, Prchal J, Turner R, Kamel-Reid S, Karsan A and Gupta V. Laboratory Investigation of Myeloproliferative Neoplasms (MPN): Recommendations of the Canadian MPN Group. Am J Clin Pathol. 2016 Oct;146(4):408-22. PMID: 27686169
  31. Patenaude A and Karsan, A. A Novel Population of Local Pericyte Precursor Cells in Tumor Stroma that Require Notch Signaling for Differentiation. J Cell Signal. 2016 May. 1:115. doi:10.4172/jcs.1000115.
  32. Lund H, Hughesman C, Fakhfakh K, McNeil K, Clemens S, Hocken K, Pettersson R, Karsan A, Foster L, Haynes C. Initial Diagnosis of ALK-Positive Non-Small-Cell Lung Cancer Based on Analysis of ALK Status Utilizing Droplet Digital PCR. Anal Chem. 2016 May 3;88(9):4879-85. PMID: 27043019
  33. Cressman S, Karsan A, Hogge D, McPherson E, Bolbocean C, Regier D, Peacock S. Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. Br J Haematol. 2016 Aug;174(4):526-35. PMID: 27098559
  34. Young S, Tucker T, Bosdet I, and Karsan A. Estimating deep molecular responses in chronic myelogenous leukemia: a Bayesian approach. Leukemia. 2016 Jul;30(7):1628-9. PMID: 26952806
  35. Parker J, Shen Y, Pleasance E,  Li Y, Schein J, Zhao Y, Moore R, Wegrzyn-Woltosz J, Savage K, Weng A, Gascoyne R, Jones S, Marra M, Laskin J, Karsan A. Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing. Cold Spring Harb Mol Case Stud. 2016 March 2. Stud  2:  a000679. PMID: 27148583
  36. Lund H, Hughesman C, McNeil K, Clemens S, Hocken K, Pettersson R, Karsan A, Foster L, Haynes C. Initial Diagnosis of Chronic Myelogenous Leukemia Based on Quantification of M-BCR Status Using Droplet Digital PCR. Anal Bioanal Chem. 2016 Feb;408(4):1079-94. PMID: 26631023
  37. Huang S, Gillan T, Gerrie A, Hrynchak M, Karsan A, Ramadan K, Smith A, Toze C, Bruyere H. Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada. Genes Chromosomes Cancer. 2016 Jan;55(1):16-24. PMID:26391112
  38. Bidshahri R, Attali D, Fakhfakh K, McNeil K, Karsan A, Won J, Wolber R, Bryan J, Hughesman C, and Haynes C. Quantitative detection and resolution of BRAF V600 status in colorectal cancer using droplet digital PCR and a novel wild-type negative assay. J Mol Diagn. 2016 Mar;18(2):190-204. PMID: 26762843 
  39. Laskin J, Jones S, Aparicio S, Chia S, Ch’ng C, Deyell R, Eirew P, Fok A, Gelmon K, Ho C, Huntsman D, Jones M, Kasaian K, Karsan A, Leelakumari S, Li Y, Lim H, Ma Y, Mar C, Martin M, Moore R, Mungall A, Mungall K, Pleasance E, Rassekh S, Renouf D, Shen Y, Schein J, Schrader K, Sun S, Tinker A, Zhao E, Yip S, and Marra M. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Cold Spring Harb Mol Case Stud. 2015 Oct 27. 1: a000570. PMID: 27148575
  40. Varney M, Niederkorn M, Konno H, Matsumura T, Gohda J, Yoshida N, Akiyama T, Christie S, Fang J, Miller D, Jerez A, Karsan A, Maciejewski J, Meetei R, Inoue J, Starczynowski D. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. J Exp Med. 2015 Oct 19;212(11):1967-85. PMID: 26458771
  41. Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun S, Mah S, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski D, Karsan A, Heuser M, Hogge D, Camargo F, Engelhardt S, Döhner H, Buske C, Jongen-Lavrencic M, Naldini L, Humphries R, Kuchenbauer F. MicroRNA-223 dose-levels fine-tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Exp Hematol. 2015 Oct;43(10):858-868.e7. PMID:26163797
  42. Patenaude A, Woerher S, Umlandt P, Wong F, Ibrahim R, Kyle A, Unger S, Fuller M, Parker J, Minchinton A, Eaves C, Karsan A. A novel population of local pericyte precursor cells in tumor stroma that require Notch signaling for differentiation. Microvasc Res. 2015 Sep;101:38-47. PMID: 26092680
  43. Lerner-Ellis J, Wang M, White S, Lebo M, Agatep R, Ainsworth P, Akbari MR, Aronson M, Bader GD, Basran R, Blavier A, Blumenthal A, Buckley K, Campbell J, Campeau PM, Care M, Carson N, Carter R, Charames G, Chitayat D, Chong G, Chouinard E, Chun K, Craddock KJ, Docking R, Eisen A, Faghfoury H, Farrell S, Feilotter H, Fernandez B, Forster-Gibson C, Foulkes W, Hegele R, Holter S, Horsburgh S, Hughes L, Hume S, Jewett F, Karsan A, Khalouei S, Knoll J, Kolomeitz E, Maire G, Marshall C, McCready E, Moorhouse MJ, Morel C, Nelson T, O'Connor B, Ouellette F, Parboosingh J, Ray P, Rehm H, Riddell C, Rosenblatt DS, Ruchon A, Sadikovic B, Semotiuk K, Scherer SW, Shuman C, Silver J, Siminovitch K, Solomon-Izsak L, Speevak M, Stavropoulos J, Stein L, Tannenbaum R, Terespolsky D, Wintle RF, Wong B, Wong N, Waye JS, Woods MO, Wyatt P, Young S. Canadian Open Genetics Repository (COGR): a unified clinical genomics database as a community resource for standardising and sharing genetic interpretations. J Med Genet. 2015 Jul;52(7):438-45. PMID:25904639
  44. McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J. 2015 Mar 13;5:e291. PMID: 25768405
  45. Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, Sehn LH, Mourad YA, Barnett MJ, Broady RC, Connors JM, Forrest DL, Gerrie AS, Hogge DE, Narayanan S, Nevill TJ, Nantel SH, Power MM, Sutherland HJ, Villa D, Shepherd JD, Song KW. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015 Jan 3. pii: S2152-2650(14)00574-6. PMID: 25656914
  46. O'Neill K, Aghaeepour N, Parker J, Hogge D, Karsan A, Dalal B, Brinkman RR. Deep profiling of multitube flow cytometry data. Bioinformatics. 2015 Jan 18. pii: btv008. PMID: 25600947

  47. Birol I, Raymond A, Chiu R, Nip KM, Jackman SD, Kreitzman M, Docking TR, Ennis CA, Robertson AG, Karsan A. Kleat: cleavage site analysis of transcriptomes. Pac Symp Biocomput.. 2015, Jan; 20:347-58. PMID: 25592595
  48. Sheffield BS, Bosdet IE, Ali RH, Young SS, McNeil BK, Wong C, Dastur K, Karsan A, Ionescu DN. Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer. Curr Oncol. 2014 Dec; 21(6):305-8. PMID: 25489257
  49. Lai CK, Moon Y, Kuchenbauer F, Starzcynowski DT, Argiropoulos B, Yung E, Beer P, Schwarzer A, Sharma A, Park G, Leung M, Lin G, Vollett S, Fung S, Eaves CJ, Karsan A, Weng AP, Humphries RK, Heuser M. Cell fate decisions in malignant hematopoiesis: leukemia phenotype is determined by distinct functional domains of the MN1 oncogene. PLoS One. 2014 Nov 17;9(11):e112671. PMID: 25401736
  50. Cutz JC, Craddock KJ, Torlakovic E, Brandao G, Carter RF, Bigras G, Deschenes J, Izevbaye I, Xu Z, Greer W, Yatabe Y, Ionescu D, Karsan A, Jung S, Fraser RF, Blumenkrantz M, Lavoie J, Fortin F, Bojarski A, Cote GB, van den Berghe JA, Rashid-Kolvear F, Trotter M, Sekhon HS, Albadine R, Tran-Thanh D, Gorska I, Knoll JHM, Xu J, Blencowe B, Iafrate AJ, Hwang DM,Pintilie M, Gaspo R, Couture C, and Tsao MS . Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. Journal of Thoracic Oncology, 2014 Sep;9(9):1255-63. PMID:25122422

  51. Gerrie A, Huang S.J,T, Bruyere H,  Chinmay D, Hrynchak M, Karsan A, Ramadan K.M, Smith A.C, Tyson C, Toze C.L, Gillian T.L. Population-based characterization of the genetic landscape of chronic lymphocytic leukemia patients referred for cytogenetic testing in British Columbia, Canada: the role of provincial laboratory standardization. Cancer Genet. 2014 Jul-Aug; 207(7-8):316-25. PMID: 2544168
  52. Kulic I, Robertson G, Chang L, Baker JHE, Lockwood WW, Mok W, Fuller M, Fournier M, Wong N, Chou V, Robinson MD, Chun H, Filks B, Kempkes B, Thomson TA, Hirst M, Minchinton AI, Lam WL, Jones S, Marra M, Karsan A. Loss of the Notch effector RPBJ promotes tumorigenesis. J Exp Med. 2015 Jan 12;212(1):37-52. doi: 10.1084/jem.20121192..
  53. Chang ACY, Garside VC, Fournier M, Smrz J, Vrljicak P, Umlandt P, Fuller M, Robertson G, Zhao Y, Tam A, Jones SJM,. Marra MA, Hoodless PA, Karsan A. A Notch-dependent transcriptional hierarchy promotes mesenchymal transdifferentiation in the cardiac cushion. Dev Dyn. 2014 Mar 16. doi: 10.1002/dvdy.24127
  54. Patenaude A, Fuller M, Chang L, Wong F, Paliouras G, Shaw R, Kyle AH, Umlandt P, Baker JH, Diaz E, Tong J, Minchinton AI, Karsan A.  Endothelial-specific Notch blockade inhibits vascular function and tumor growth through an eNOS-dependent mechanism.  Cancer Res. 2014 May 1;74(9):2402-11.
  55. Mariano C, Bosdet I, Karsan A, Ionescu D, Murray N, Laskin JJ, Zhai Y, Melosky B, Sun S, Ho C. A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease. Lung Cancer. 2014 Jan;83(1):73-7.
  56. Wilson IM, Vucic EA, Enfield KSS, Thu KL, Zhang YA, Chari R, Lockwood WW, Radulovich N, Starczynowski DT, Banáth JP, Zhang M, Pusic A, Fuller M, Lonergan KM, Rowbotham D, Yee J, English JC, Buys TPH, Selamat SA, Laird-Offringa IA, Liu P, Anderson M, You M, Tsao MS, Brown CJ, Bennewith KL, MacAulay CE, Karsan A, Gazdar AF, Lam S, and Lam WL.  EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk. Oncogene. 2013 Oct 7. doi: 10.1038/onc.2013.396. [Epub ahead of print].
  57. El-Sehemy A, Chang A, Azad AK, Gupta N, Xu Z, Steed H, Karsan A, Fu YX. Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells. Cell Signal. 2013 Dec;25(12):2780-7. doi: 10.1016/j.cellsig.2013.09.008. Epub 2013 Sep 13
  58. Bosdet IE, Docking TR, Butterfield YS, Mungall AJ, Zeng T, Coope RJ, Yorida E, Chow K, Bala M, Young SS, Hirst M, Birol I, Moore RA, Jones SJ, Marra MA, Holt R, Karsan A. A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations. J Mol Diagn. 2013 Sep 25. pii: S1525-1578(13)00135-9. doi: 10.1016/j.jmoldx.2013.07.004.
  59. Swanson L, Robertson G, Mungall KL, Butterfield YS, Chiu R, Corbett RD, Docking TR, Hogge D, Jackman SD, Moore RA, Mungall AJ, Nip KM, Parker JD, Qian JQ, Raymond A, Sung S, Tam A, Thiessen N, Varhol R, Wang S, Yorukoglu D, Zhao Y, Hoodless PA, Sahinalp SC, Karsan A, Birol I. Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies. BMC Genomics. 2013 Aug 14;14:550. doi: 10.1186/1471-2164-14-550.
  60. Dauphinee SM, Clayton A, Hussainkhel A, Yang C, Park YJ, Fuller ME, Blonder J, Veenstra TD, Karsan A. SASH1 is a scaffold molecule in endothelial TLR4 signaling. J Immunol. 2013 Jul 15;191(2):892-901. doi: 10.4049/jimmunol.1200583. Epub 2013 Jun 17.
  61. Chang L, Wong F, Niessen K, Karsan A. Notch activation promotes endothelial survival through a PI3K-Slug axis. Microvasc Res. 2013 Sep;89:80-5. doi: 10.1016/j.mvr.2013.05.007. Epub 2013 Jun 3.
  62. Ley TJ, Miller CA, Ding L, Raphael BJ, Mungall AJ, Robertson AG, Hoadley KA, Triche Jr TJ, Laird PW, Baty JD, Fulton LL, Fulton RS, Heath SE, Kalicki-Veizer J, Kandoth C, Klco JM, Koboldt DC, Kanchi K-L, Kulkarni S, Lamprecht TL, Larson DE, Lin L, Lu C, McLellan MD, McMichael JF, Payton JE, Schmidt H, Spencer DH, Tomasson MH, Wallis JW, Wartman LD, Watson MA, Welch JS, Wendl MC, Ally A, Balasundaram M, Birol I, Butterfield YSN, Chiu R, Chu A, Chuah E, Chun H-J E, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Jones S JM, Karsan A, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall LL, Parker J, Pleasance E, Plettner P, Schein JE, Stoll D, Swanson L, Tam A, Thiessen N, Varhol RJ, Wye N, Zhao Y, Gabriel SGG, Sougnez C, Zou L, Leiserson MDM, Vandin F, Wu H-T, Appelbaum F, Baylin SB, Akbani R, Broom BM, Chen K, Motter TC, Nguyen K, Weinstein JN, Zhang N, Ferguson ML, Adams C, Black A, Bowen J, Gastier-Foster JM, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok JA, Mills Shaw KR, Sheth M, Sofia HJ, Yang L, Downing JR, Eley G, Alonso S, Ayala B, Baboud J, Backus M, Barletta SP, Berton DL, Chu AL, Girshik S, Jensen MA, Kahn AB, Kothiyal P, Nicholls MC, Pihl TD, Pot DA, Raman R, Sanbhadti RN, Snyder EE, Srinivasan D, Walton J, Wan Y, Wang Z, Issa J-P, Le Beau M, Carroll M, Kantarjian H, Kornblau S, Bootwalla MS, Lai PH, Shen H, Van Den Berg DJ, Weisenberger DJ, Link DC, Walter MJ, Ozenberger BA, Mardis ER, Westervelt P, Graubert TA, DiPersio JF, Wilson RK.  The Genomic and Epigenomic Landscape of Adult de novo Acute Myeloid Leukemia, N Engl J Med. 2013 May 30;368(22):2059-74. PMID:23634996
  63. Venner CP, Woltosz JW, Nevill TJ, Deeg HJ, Caceres G, Platzbecker U, Scott BL, Sokol L, Sung S, List AF, Karsan A. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome. Haematologica. 2013 March; 98(3): 409–413. doi: 10.3324/haematol.2012.066068
  64. Wilson IM, Vucic EA, Enfield KS, Thu KL, Zhang YA, Chari R, Lockwood WW, Radulovich N, Starczynowski DT, Banáth JP, Zhang M, Pusic A, Fuller M, Lonergan KM, Rowbotham D, Yee J, English JC, Buys TP, Selamat SA, Laird-Offringa IA, Liu P, Anderson M, You M, Tsao MS, Brown CJ, Bennewith KL, Macaulay CE, Karsan A, Gazdar AF, Lam S, Lam WL. EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk. Oncogene. 2013 Oct 7. doi: 10.1038/onc.2013.396. [Epub ahead of print]
  65. Chang ACY, Patenaude A, Lu K, Fuller M, Ly M, Kyle A, Golbidi S, Wang Y, Walley K, Minchinton A, Laher I, Karsan A. Notch-Dependent Regulation of the Ischemic Vasodilatory Response--Brief Report. Arterioscler Thromb Vasc Biol. 2013;33:510-512.
  66. Garside V, Chang AC, Karsan A, Hoodless PA. Co-ordinating Notch, BMP, and TGFβ Signalling During Heart Valve Development. Cell Mol Life Sci. 2013 Aug;70(16):2899-917. PMID:23161060. Author's final copy
  67. Chang L, Noseda M, Higginson M, Ly M, Patenaude A, Fuller M, Kyle AH, Minchinton AI, Puri MC, Dumont DJ, Karsan A. Differentiation of vascular smooth muscle cells from local precursors during embryonic and adult arteriogenesis requires Notch signaling. Proc Natl Acad Sci U S A. 2012 May 1;109(18):6993-8. Epub 2012 Apr 16. PubMed PMID: 22509029; PubMed Central PMCID: PMC3345008. Author's final copy
  68. Venner CP, Wegrzyn Woltosz J, Nevill TJ, Deeg HJ, Caceres G, Platzbecker U, Scott BL, Sokol L, Sung S, List AF, Karsan A. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome. Haematologica. 2013 Mar;98(3):409-13. doi: 10.3324/haematol.2012.066068. Epub 2012 Aug 28.
  69. Wong NKY, Fuller M, Sung S, Wong F, Karsan A. Heterogeneity of breast cancer stem cells as evidenced with Notch-dependent and Notch-independent populations, Cancer Medicine, Article first published online : 18 JUL 2012, DOI: 10.1002/cam4.18. Open access.
  70. Vrljicak P, Cullum R, Xu E, Chang AC, Wederell ED, Bilenky M, Jones SJ, Marra MA, Karsan A, Hoodless PA. Twist1 transcriptional targets in the developing atrio-ventricular canal of the mouse. PLoS One. 2012;7(7):e40815. Epub 2012 Jul 16. Open access.
  71. Vercauteren SM, Starczynowski DT, Sung S, McNeil K, Salski C, Jensen C-L, Bruyere H, Lam WL, Karsan A. T cells of patients with myelodysplastic syndrome are frequently derived from the  malignant clone.  Brit J Haematol 2012 Feb 156(3): 402–414. Open access.
  72. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis DN, Maslova A, Moore R, Moradian A, Mungall KL, Perizzolo M, Qian J, Roldan G, Smith EE, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall AJ, Jones SJ, Morin GB, Chan JA, Cairncross JG, Marra MA. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012 Jan;226(1):7-16.
  73. Dauphinee SM, Voelcker V, Tebaykina Z, Wong F, Karsan A. Heterotrimeric Gi/Go proteins modulate endothelial TLR signaling independent of the MyD88-dependent pathway. Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2246-53.
  74. Vercauteren, SM, Karsan, A. Myelodysplastic Syndromes – Evolving Insights.  Can J Pathol. 2011 3(4):31-37.
  75. Karsan, A. The biology of myelodysplastic syndromes. Hematology Education: 2011; 5:217-226.
  76. Starczynowski DT, Lockwood WW, Deléhouzée S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL, Karsan A. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Invest. 2011 Oct 3;121(10):4095-105.
  77. Kuchenbauer F, Mah SM, Heuser M, McPherson A, Rüschmann J, Rouhi A, Berg T, Bullinger L, Argiropoulos B, Morin RD, Lai D, Starczynowski DT, Karsan A, Eaves CJ, Watahiki A, Wang Y, Aparicio SA, Ganser A, Krauter J, Döhner H, Döhner K, Marra MA, Camargo FD, Palmqvist L, Buske C, Humphries RK. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood. 2011 Sep 22;118(12):3350-8.
  78. Chang AC, Fu Y, Garside VC, Niessen K, Chang L, Fuller M, Setiadi A, Smrz J, Kyle A, Minchinton A, Marra M, Hoodless PA, Karsan A. Notch initiates the endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of soluble guanylyl cyclase. Dev Cell. 2011 Aug 16;21(2):288-300
  79. Wegrzyn J, Lam JC, Karsan A. Mouse models of myelodysplastic syndromes. Leuk Res. 2011 Jul;35(7):853-62. Epub 2011 Apr 3. Review
  80. Fu Y, Chang AC, Fournier M, Chang L, Niessen K, Karsan A. RUNX3 maintains the mesenchymal phenotype after termination of the Notch signal. J Biol Chem. 2011 Apr 1;286(13):11803-13
  81. Starczynowski DT, Vercauteren S, Sung S, Brooks-Wilson A, Lam WL, Karsan A.Copy number alterations at polymorphic loci may be acquired somatically in patients with myelodysplastic syndromes. Leuk Res. 2011 Apr;35(4):444-7.Authors Proof
  82. Jädersten M, Karsan A. Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring. Haematologica. 2011 Feb;96(2):177-80.
  83. Starczynowski DT, Kuchenbauer F, Wegrzyn J, Rouhi A, Petriv O, Hansen CL, Humphries RK, Karsan A. MicroRNA-146a disrupts hematopoietic differentiation and survival.Exp Hematol. 2011 Feb;39(2):167-178.e4.Authors Proof
  84. Starczynowski DT, Morin R, McPherson A, Lam J, Chari R, Wegrzyn J, Kuchenbauer F, Hirst M, Tohyama K, Humphries RK, Lam WL, Marra M, Karsan A. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood. 2011 Jan 13;117(2):595-607.Authors proof
  85. Farinha P, Kyle AH, Minchinton AI, Connors JM, Karsan A, Gascoyne RD. Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica. 2010 Dec;95(12):2157-60. Epub 2010 Aug 16.
  86. Vercauteren SM, Sung S, Starczynowski DT, Lam WL, Bruyere H, Horsman DE, Tsang P, Leitch H, Karsan A. Array comparative genomic hybridization of peripheral blood granulocytes of patients with myelodysplastic syndrome detects karyotypic abnormalities. Am J Clin Pathol. 2010 Jul;134(1):119-26. Authors Proof
  87. Starczynowski DT, Karsan A. Innate immune signaling in the myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010 Apr;24(2):343-59.Authors Proof
  88. Starczynowski DT, Karsan A. Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle. 2010 Mar 1;9(5):855-6. Epub 2010 Mar 11. Authors proof
  89. Murphy D, Parker J, Zhou M, Fadlelmola FM, Steidl C, Karsan A, Gascoyne RD, Chen H, Banerjee D. Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B). Mol Cancer. 2010 Jan 26;9:14.
  90. Patenaude A, Parker J, Karsan A. Involvement of endothelial progenitor cells in tumor vascularization. Microvasc Res. 2010 May;79(3):217-23. Epub 2010 Jan 18.
  91. Vrljicak P, Chang AC, Morozova O, Wederell ED, Niessen K, Marra MA, Karsan A, Hoodless PA. Genomic analysis distinguishes phases of early development of the mouse atrio-ventricular canal. Physiol Genomics. 2010 Feb 4;40(3):150-7. Epub 2009 Dec 1.
  92. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010 Jan;16(1):49-58. Epub 2009 Nov 8.Authors Proof
  93. Fu Y, Chang A, Chang L, Niessen K, Eapen S, Setiadi A, Karsan A. Differential regulation of transforming growth factor beta signaling pathways by Notch in human endothelial cells. J Biol Chem. 2009 Jul 17;284(29):19452-62. Epub 2009 May 27.
  94. Vercauteren SM, Bashashati A, Wu D, Brinkman RR, Eaves C, Eaves A, Karsan A. Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias. Leuk Res. 2009 Dec;33(12):1636-42. Epub 2009 May 2.
  95. Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A, Spinelli JJ, Eaves CJ, Eaves AC, Horsman DE, Lam WL, Karsan A. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood. 2008 Oct 15;112(8):3412-24. Epub 2008 Jul 28.
  96. Niessen K, Fu Y, Chang L, Hoodless PA, McFadden D, Karsan A. Slug is a direct Notch target required for initiation of cardiac cushion cellularization. J Cell Biol. 2008 Jul 28;182(2):315-25.
  97. Niessen K, Karsan A. Notch signaling in cardiac development. Circ Res. 2008 May 23;102(10):1169-81. Review.
  98. Karsan A. Notch and integrin affinity: a sticky situation. Sci Signal. 2008 Jan 15;1(2):pe2.
  99. Leong KG, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I, Karsan A. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med. 2007 Nov 26;204(12):2935-48. Epub 2007 Nov 5.
  100. Zhande R, Dauphinee SM, Thomas JA, Yamamoto M, Akira S, Karsan A. FADD negatively regulates lipopolysaccharide signaling by impairing interleukin-1 receptor-associated kinase 1-MyD88 interaction. Mol Cell Biol. 2007 Nov;27(21):7394-404. Epub 2007 Sep 4.
  101. Wu C, Cipollone J, Maines-Bandiera S, Tan C, Karsan A, Auersperg N, Roskelley CD. The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression. Differentiation. 2008 Feb;76(2):193-205. Epub 2007 Jul 2.
  102. Larrivée B, Karsan A. Involvement of marrow-derived endothelial cells in vascularization. Handb Exp Pharmacol. 2007;(180):89-114. Review.
  103. Niessen K, Karsan A. Notch signaling in the developing cardiovascular system. Am J Physiol Cell Physiol. 2007 Jul;293(1):C1-11. Epub 2007 Mar 21. Review.
  104. Zhande R, Karsan A. Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-kappaB-independent upregulation of Bcl-xL. Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2467-74. Epub 2007 Jan 19.
  105. Noseda M, Karsan A. Notch and minichromosome maintenance (MCM) proteins: integration of two ancestral pathways in cell cycle control. Cell Cycle. 2006 Dec;5(23):2704-9. Epub 2006 Dec 1. Review.
  106. Larrivée B, Olive PL, Karsan A. Tissue distribution of endothelial cells in vivo following intravenous injection. Exp Hematol. 2006 Dec;34(12):1741-5.
  107. Noseda M, Fu Y, Niessen K, Wong F, Chang L, McLean G, Karsan A. Smooth Muscle alpha-actin is a direct target of Notch/CSL. Circ Res. 2006 Jun 23;98(12):1468-70. Epub 2006 Jun 1.
  108. Dauphinee SM, Karsan A. Lipopolysaccharide signaling in endothelial cells. Lab Invest. 2006 Jan;86(1):9-22. Review.
  109. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006 Mar 15;107(6):2223-33. Epub 2005 Nov 15. Review.
  110. Murphy S, Larrivée B, Pollet I, Craig KS, Williams DE, Huang XH, Abbott M, Wong F, Curtis C, Conrads TP, Veenstra T, Puri M, Hsiang Y, Roberge M, Andersen RJ, Karsan A. Identification of sokotrasterol sulfate as a novel proangiogenic steroid. Circ Res. 2006 Aug 4;99(3):257-65. Epub 2006 Jun 22.
  111. Larrivée B, Pollet I, Karsan A. Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor. J Immunol. 2005 Sep 1;175(5):3015-24.
  112. Larrivée B, Niessen K, Pollet I, Corbel SY, Long M, Rossi FM, Olive PL, Karsan A. Minimal contribution of marrow-derived endothelial precursors to tumor vasculature. J Immunol. 2005 Sep 1;175(5):2890-9.
  113. Harfouche R, Malak NA, Brandes RP, Karsan A, Irani K, Hussain SN. Roles of reactive oxygen species in angiopoietin-1/tie-2 receptor signaling. FASEB J. 2005 Oct;19(12):1728-30. Epub 2005 Jul 27.
  114. Hood BL, Lucas DA, Kim G, Chan KC, Blonder J, Issaq HJ, Veenstra TD, Conrads TP, Pollet I, Karsan A. Quantitative analysis of the low molecular weight serum proteome using 18O stable isotope labeling in a lung tumor xenograft mouse model. J Am Soc Mass Spectrom. 2005 Aug;16(8):1221-30.
  115. Noseda M, Niessen K, McLean G, Chang L, Karsan A. Notch-dependent cell cycle arrest is associated with downregulation of minichromosome maintenance proteins. Circ Res. 2005 Jul 22;97(2):102-4. Epub 2005 Jun 23.
  116. Karsan A, Eigl BJ, Flibotte S, Gelmon K, Switzer P, Hassell P, Harrison D, Law J, Hayes M, Stillwell M, Xiao Z, Conrads TP, Veenstra T. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem. 2005 Aug;51(8):1525-8. Epub 2005 Jun 10.
  117. Karsan A, Blonder J, Law J, Yaquian E, Lucas DA, Conrads TP, Veenstra T. Proteomic analysis of lipid microdomains from lipopolysaccharide-activated human endothelial cells. J Proteome Res. 2005 Mar-Apr;4(2):349-57.
  118. Karsan A. The role of notch in modeling and maintaining the vasculature. Can J Physiol Pharmacol. 2005 Jan;83(1):14-23. Review.
  119. Karsan A, Pollet I, Yu LR, Chan KC, Conrads TP, Lucas DA, Andersen R, Veenstra T. Quantitative proteomic analysis of sokotrasterol sulfate-stimulated primary human endothelial cells. Mol Cell Proteomics. 2005 Feb;4(2):191-204. Epub 2004 Dec 20.
  120. Noseda M, Chang L, McLean G, Grim JE, Clurman BE, Smith LL, Karsan A. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol. 2004 Oct;24(20):8813-22.
  121. Larrivée B, Karsan A. Isolation and culture of primary endothelial cells. Methods Mol Biol. 2005;290:315-29.
  122. MacKenzie F, Duriez P, Larrivée B, Chang L, Pollet I, Wong F, Yip C, Karsan A. Notch4-induced inhibition of endothelial sprouting requires the ankyrin repeats and involves signaling through RBP-Jkappa. Blood. 2004 Sep 15;104(6):1760-8. Epub 2004 Jun 8.
  123. Wong F, Hull C, Zhande R, Law J, Karsan A. Lipopolysaccharide initiates a TRAF6-mediated endothelial survival signal. Blood. 2004 Jun 15;103(12):4520-6. Epub 2004 Mar 2.
  124. Noseda M, McLean G, Niessen K, Chang L, Pollet I, Montpetit R, Shahidi R, Dorovini-Zis K, Li L, Beckstead B, Durand RE, Hoodless PA, Karsan A. Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. Circ Res. 2004 Apr 16;94(7):910-7. Epub 2004 Feb 26.
  125. MacKenzie F, Duriez P, Wong F, Noseda M, Karsan A. Notch4 inhibits endothelial apoptosis via RBP-Jkappa-dependent and -independent pathways. J Biol Chem. 2004 Mar 19;279(12):11657-63. Epub 2003 Dec 29.
  126. Harfouche R, Gratton JP, Yancopoulos GD, Noseda M, Karsan A, Hussain SN. Angiopoietin-1 activates both anti- and proapoptotic mitogen-activated protein kinases. FASEB J. 2003 Aug;17(11):1523-5. Epub 2003 Jun 17.
  127. Pollet I, Opina CJ, Zimmerman C, Leong KG, Wong F, Karsan A. Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-kappaB and c-Jun N-terminal kinase. Blood. 2003 Sep 1;102(5):1740-2. Epub 2003 Apr 24.
  128. Larrivée B, Lane DR, Pollet I, Olive PL, Humphries RK, Karsan A. Vascular endothelial growth factor receptor-2 induces survival of hematopoietic progenitor cells. J Biol Chem. 2003 Jun 13;278(24):22006-13. Epub 2003 Mar 30.
  129. Levkau B, Kenagy RD, Karsan A, Weitkamp B, Clowes AW, Ross R, Raines EW. Activation of metalloproteinases and their association with integrins: an auxiliary apoptotic pathway in human endothelial cells. Cell Death Differ. 2002 Dec;9(12):1360-7.
  130. Zheng X, Karsan A, Duronio V, Chu F, Walker DC, Bai TR, Schellenberg RR. Interleukin-3, but not granulocyte-macrophage colony-stimulating factor and interleukin-5, inhibits apoptosis of human basophils through phosphatidylinositol 3-kinase: requirement of NF-kappaB-dependent and -independent pathways. Immunology. 2002 Nov;107(3):306-15.
  131. Hull C, McLean G, Wong F, Duriez PJ, Karsan A. Lipopolysaccharide signals an endothelial apoptosis pathway through TNF receptor-associated factor 6-mediated activation of c-Jun NH2-terminal kinase. J Immunol. 2002 Sep 1;169(5):2611-8.
  132. Litwin C, Leong KG, Zapf R, Sutherland H, Naiman SC, Karsan A. Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia. Am J Hematol. 2002 May;70(1):22-30.
  133. Leong KG, Hu X, Li L, Noseda M, Larrivée B, Hull C, Hood L, Wong F, Karsan A. Activated Notch4 inhibits angiogenesis: role of beta 1-integrin activation. Mol Cell Biol. 2002 Apr;22(8):2830-41.
  134. Roskelley CD, Williams DE, McHardy LM, Leong KG, Troussard A, Karsan A, Andersen RJ, Dedhar S, Roberge M. Inhibition of tumor cell invasion and angiogenesis by motuporamines. Cancer Res. 2001 Sep 15;61(18):6788-94.
  135. Churg A, Dai J, Zay K, Karsan A, Hendricks R, Yee C, Martin R, MacKenzie R, Xie C, Zhang L, Shapiro S, Wright JL. Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest. 2001 Aug;81(8):1119-31.
  136. Imanishi T, Hano T, Nishio I, Han DK, Schwartz SM, Karsan A. Apoptosis of vascular smooth muscle cells is induced by Fas ligand derived from endothelial cells. Jpn Circ J. 2001 Jun;65(6):556-60. Erratum in: Jpn Circ J 2002 Dec;66(12):1185.
  137. Leong KG, Karsan A. Signaling pathways mediated by tumor necrosis factor alpha. Histol Histopathol. 2000 Oct;15(4):1303-25. Review.
  138. Duriez PJ, Wong F, Dorovini-Zis K, Shahidi R, Karsan A. A1 functions at the mitochondria to delay endothelial apoptosis in response to tumor necrosis factor. J Biol Chem. 2000 Jun 16;275(24):18099-107.
  139. Larrivée B, Karsan A. Signaling pathways induced by vascular endothelial growth factor (review). Int J Mol Med. 2000 May;5(5):447-56. Review.
  140. Zen K, Karsan A, Stempien-Otero A, Yee E, Tupper J, Li X, Eunson T, Kay MA, Wilson CB, Winn RK, Harlan JM. NF-kappaB activation is required for human endothelial survival during exposure to tumor necrosis factor-alpha but not to interleukin-1beta or lipopolysaccharide. J Biol Chem. 1999 Oct 1;274(40):28808-15.
  141. Schwartz BR, Karsan A, Bombeli T, Harlan JM. A novel beta 1 integrin-dependent mechanism of leukocyte adherence to apoptotic cells. J Immunol. 1999 Apr 15;162(8):4842-8.
  142. Stempien-Otero A, Karsan A, Cornejo CJ, Xiang H, Eunson T, Morrison RS, Kay M, Winn R, Harlan J. Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. J Biol Chem. 1999 Mar 19;274(12):8039-45.
  143. Mitra D, Kim J, MacLow C, Karsan A, Laurence J. Role of caspases 1 and 3 and Bcl-2-related molecules in endothelial cell apoptosis associated with thrombotic microangiopathies. Am J Hematol. 1998 Dec;59(4):279-87.
  144. Hu X, Yee E, Harlan JM, Wong F, Karsan A. Lipopolysaccharide induces the antiapoptotic molecules, A1 and A20, in microvascular endothelial cells. Blood. 1998 Oct 15;92(8):2759-65.
  145. Zen K, Karsan A, Eunson T, Yee E, Harlan JM. Lipopolysaccharide-induced NF-kappaB activation in human endothelial cells involves degradation of IkappaBalpha but not IkappaBbeta. Exp Cell Res. 1998 Sep 15;243(2):425-33.
  146. Chuang PI, Yee E, Karsan A, Winn RK, Harlan JM. A1 is a constitutive and inducible Bcl-2 homologue in mature human neutrophils. Biochem Biophys Res Commun. 1998 Aug 19;249(2):361-5.
  147. Choi KB, Wong F, Harlan JM, Chaudhary PM, Hood L, Karsan A. Lipopolysaccharide mediates endothelial apoptosis by a FADD-dependent pathway. J Biol Chem. 1998 Aug 7;273(32):20185-8.
  148. Karsan A, Cornejo CJ, Winn RK, Schwartz BR, Way W, Lannir N, Gershoni-Baruch R, Etzioni A, Ochs HD, Harlan JM. Leukocyte Adhesion Deficiency Type II is a generalized defect of de novo GDP-fucose biosynthesis. Endothelial cell fucosylation is not required for neutrophil rolling on human nonlymphoid endothelium. J Clin Invest. 1998 Jun 1;101(11):2438-45.
  149. Karsan A, Yee E, Poirier GG, Zhou P, Craig R, Harlan JM. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am J Pathol. 1997 Dec;151(6):1775-84.
  150. Slowik MR, Min W, Ardito T, Karsan A, Kashgarian M, Pober JS. Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by interleukin-1-converting enzyme-like protease-dependent and -independent pathways. Lab Invest. 1997 Sep;77(3):257-67.
  151. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood. 1997 Apr 1;89(7):2429-42.
  152. Pang XP, Hershman JM, Karsan A. TNF-alpha induction of A1 expression in human cancer cells. Oncol Res. 1997;9(11-12):623-7.
  153. Karsan A, Yee E, Harlan JM. Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, A1. J Biol Chem. 1996 Nov 1;271(44):27201-4.
  154. Karsan A, Yee E, Kaushansky K, Harlan JM. Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells. Blood. 1996 Apr 15;87(8):3089-96.
  155. Karsan A, Harlan JM. Modulation of endothelial cell apoptosis: mechanisms and pathophysiological roles. J Atheroscler Thromb. 1996;3(2):75-80. Review.
  156. Karsan A, Gascoyne RD, Coupland RW, Shepherd JD, Phillips GL, Horsman DE. Combination of t(14;18) and a Burkitt's type translocation in B-cell malignancies. Leuk Lymphoma. 1993 Aug;10(6):433-41.
  157. Karsan A, Maclaren I, Conn D, Wadsworth L. An evaluation of hemoglobin determination using sodium lauryl sulfate. Am J Clin Pathol. 1993 Aug;100(2):123-6.
  158. Karsan A, MacLaren I, Pi D, Wadsworth L. Clinically significant heparin carryover on the ACL 300R. Am J Clin Pathol. 1992 Aug;98(2):240-2.

There are currently no criteria on which to search. Please add them using the 'criteria' tab.

Page last modified Jul 04, 2018